G1 Therapeutics competitors

G1 Therapeutics's competitors include OSE Immunotherapeutics, Alpine Immune Sciences, Syndax Pharmaceuticals and Bellicum Pharmaceuticals
Add company...
G1 Therapeutics
G1 is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer.
OSE Immunotherapeutics
OSE Immunotherapeutics (Nantes – ISIN : FR0012127173 ; Mnemo : OSE) was created in May 2016 through the merger of OSE Pharma, an immuno-oncology company developing specific immunotherapy activating T lymphocytes, and Effimune, a biotechnology company specializing in immune regulation with clinical applications in autoimmunity, transplantation and immuno-oncology.
Alpine Immune Sciences
Modern therapies targeting the immune synapse.
Syndax Pharmaceuticals
Syndax Pharmaceuticals is a late-stage clinical development oncology company focused on overcoming the problem of resistance in cancer therapy.
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering and developing first-in-class cellular immunotherapies for hematological cancers and solid tumors.
Founding Date
Founding Date
2008
Founding Date
2012
Founding Date
2015
Founding Date
2005
Founding Date
2004
Type
Type
Public
Type
Public
Type
Private
Type
Public
Type
Public
Tags
Locations
Locations
Durham, US HQ
Locations
Nantes, FR HQ
Paris, FR
Locations
Seattle, US HQ
Locations
Waltham, US HQ
Locations
Houston, US HQ
Employees
Employees
3827% increase
Employees
2618% increase
Employees
N/A
Employees
3237% decrease
Employees
110
Valuation ($)
Valuation ($)
1.5 b
Valuation ($)
60.5 m
Valuation ($)
N/A
Valuation ($)
206 m
Valuation ($)
420.2 m
Twitter followers
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
166
Twitter followers
108
Twitter followers
346

Funding

Total funding raised
Total funding raised
$ 92.5m
Total funding raised
$ 10.3m
Total funding raised
$ 49.3m
Total funding raised
N/A
Total funding raised
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles

OSE Immunotherapeutics
HQ
Nantes, FR
Employees
26↑ 18% increase

OSE Immunotherapeutics (Nantes – ISIN : FR0012127173 ; Mnemo : OSE) was created in May 2016 through the merger of OSE Pharma, an immuno-oncology company developing specific immunotherapy activating T lymphocytes, and Effimune, a biotechnology company specializing in immune regulation with clinical applications in autoimmunity, transplantation and immuno-oncology.

View company
Alpine Immune Sciences
HQ
Seattle, US

Modern therapies targeting the immune synapse.

View company
Syndax Pharmaceuticals
HQ
Waltham, US
Employees
32↓ 37% decrease

Syndax Pharmaceuticals is a late-stage clinical development oncology company focused on overcoming the problem of resistance in cancer therapy.

View company
Bellicum Pharmaceuticals
HQ
Houston, US
Employees
110

Bellicum Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering and developing first-in-class cellular immunotherapies for hematological cancers and solid tumors.

View company